Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function

Dapagliflozin in peritoneal dialysis patients: a pilot study evaluating peritoneal membrane function

Abstract Background Patients taking SGLT-2 inhibitors may experience delayed peritoneal fibrosis, better ultrafiltration of water and toxins, and higher survival rates. We aimed to evaluate the possible effects of Dapagliflozin in changing the peritoneal solute transfer rate, reducing peritoneal glu...

Full description

Bibliographic Details
Main Authors: Zakaria Hamdan, Yusri Abdel-Hafez, Ahmad Enaya, Alaa Sarsour, Lubna Kharraz, Zaher Nazzal
Format: Article
Language:English
Published: BMC 2024-01-01
Series:BMC Nephrology
Subjects:
Peritoneal dialysis
Dapagliflozin
Ultra-filtration failure
SGLT-2 inhibitors
Online Access:https://doi.org/10.1186/s12882-023-03429-2

Internet

https://doi.org/10.1186/s12882-023-03429-2

Similar Items